The Peptide NewsroomPeptide research, industry and supply-chain headlines

Alberta Team Asks Why Semaglutide Works for Some Patients and Not Others

Topic card: semaglutide

A University of Alberta research team writing in The Conversation says the reason semaglutide produces very different results from one person to the next may come down to how individual bodies burn energy. The group is recruiting participants now for a six-month study using a rare measurement facility.

Semaglutide, sold as Ozempic and Wegovy, is a GLP-1 receptor agonist that helps regulate blood sugar, appetite and body weight. The authors describe it acting on the brain to increase fullness and decrease appetite, and note that research has shown GLP-1 medications reduce body weight by an average of 15 percent when used weekly for 68 weeks alongside lifestyle interventions.

Why an average hides the story

That 15 percent figure is an average, and averages are exactly where the interesting variation gets buried. The team says it is exploring whether individual responses trace back to genetics, metabolism, body composition, lifestyle, microbiota, associated diseases, age and sex.

Weight is also only one measure. The authors note research has shown semaglutide medications to improve quality of life, blood markers such as sugar or cholesterol, strength and overall health, which means a patient the scale calls a non-responder may not be one.

The dimming light bulb

The mechanism the group is most interested in is metabolic adaptation, also called adaptive thermogenesis. When we lose weight the body needs less energy, but sometimes it enters an extra energy-saving mode and burns even fewer calories than expected.

The authors compare it to a light bulb that automatically dims to save electricity, and offer it as one reason weight loss gets harder over time and plateaus appear. Both fat and fat-free mass use energy at rest, so losing either tissue lowers the baseline burn.

A room that measures calories

Alberta has a whole-room indirect calorimeter, described as a rare facility resembling a hotel suite that precisely measures each component of energy use at rest, after eating and during exercise. Participants with insulin resistance or diabetes who are about to start semaglutide will be followed for six months.

Limitations

No results exist yet: recruitment is ongoing and the study is prospective. The team's own published review of GLP-1 therapies and energy utilization found only a few studies on how semaglutide affects resting energy use, with findings the authors call neutral or inconclusive.

An open question, honestly labeled

The authors say how semaglutide impacts energy use is an emerging area and remains an open question. Their stated goal is anticipating non-responders earlier so alternatives can be offered sooner.

Source: ScienceDaily — Pharmacology. Read the original.

Filed under: glp-1

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

What the Research Actually Says About Semaglutide, From Weight Loss to Memory

Semaglutide has large human trials behind its weight and metabolic outcomes, but the newer questions about energy expenditure, muscle preservation and cognition are far less settled. A digest of what researchers have actually reported, and where the evidence stops.

Kemin Pitches Positive Aging, GLP-1 Support and Gut Health as Its 2027 Trends

Kemin's Filipa Quintela told Nutritional Outlook at SupplySide Global that positive aging, GLP-1 support through Slendesta, and gut health via the Gutopia platform will shape the supplier's 2027 development. She also put American lutein intake at around 2 mg a day against an optimal 10 mg.

Ingredient Supplier Kemin Puts GLP-1 Companion Nutrition at the Center of Its 2027 Outlook

At SupplySide Global, ingredient developer Kemin outlined a 2027 wellness outlook built on GLP-1 companion nutrition, gut health, and positive aging, with FloraGLO Lutein repositioned toward cognition. No trial data or outcome figures appear anywhere in the coverage, which makes this a supplier forecast rather than new evidence.